Synapse - Gabrielle Nicole Melamed

Gabrielle Nicole Melamed

Research Focus

Medicine; Research Project Manager

Recent additions – View all

A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
Meeting Abstract

Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
Blood (2023)

Fulltext@MSK | Save

Co-authors at MSK

1

Abdel-Wahab
1

Derkach
1

Intlekofer
1

Levine
1

Stein
1

Thompson

Types of Work

Publications

Blood (1)